Major advances were made in the treatment of chronic myeloid leukaemias and gastrointestinal tumours by using drugs that directly inhibit the pathways deregulated by the BCL2-ABL fusion gene and c-KIT mutations (Hochhaus, 2004). Here, BCL2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.